AC
SCNI

Armistice Capital’s Scinai Immunotherapeutics SCNI Stock Holding History

Armistice Capital’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-12,179
Closed -$63.2K – 364
2024
Q1 		$63.2K Sell
12,179
-10,911
-47% -$56.3K ﹤0.01% 313
2023
Q4 		$137K Sell
23,090
-13,155
-36% -$90.5K ﹤0.01% 250
2023
Q3 		$315K Buy
+36,245
New +$465K ﹤0.01% 180

Other funds holding SCNI

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
APC
Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return
MSG
Main Street Group Glen Allen, Virginia $429M AUM 34.03% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $5.64B AUM

Armistice Capital's SCNI Position: Q2 2024 in Review

Armistice Capital sold out of Scinai Immunotherapeutics (SCNI) in Q2 2024, closing a stake of 12,179 shares — an estimated $63.2K sold.

Armistice Capital first reported a position in SCNI in Q3 2023 and held it in 3 quarters. The position peaked at $315K in Q3 2023. 9 funds tracked by Wall St. Rank hold SCNI as of Q2 2024.

  • Armistice Capital reported no remaining Scinai Immunotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Armistice Capital sold 12,179 Scinai Immunotherapeutics shares in Q2 2024, an estimated $63.2K.
  • Armistice Capital first reported a position in Scinai Immunotherapeutics in Q3 2023 and held it in 3 quarters.
  • Armistice Capital's Scinai Immunotherapeutics position peaked at $315K in Q3 2023.
  • 9 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q2 2024.

Based on Armistice Capital's 13F filing for Q2 2024, filed 14 Aug 2024.